OpGen Stock Soars 840% As Subsidiary Curetis Receives Substantial Payment

In an exciting development for Unit Curetis GmbH, a substantial payment of 750,000 Euros has been received. This payment is directly linked to the successful sale of specific Unyvero A50 systems to a strategic partner. The transaction signifies a significant milestone for OpGen’s Subsidiary Curetis, further solidifying their position in the market.

OpGen shares soared 840% in premarket trading Thursday.

The receipt of this payment highlights the trust and confidence placed in Unit Curetis GmbH and their cutting-edge products. With the Unyvero A50 systems gaining recognition for their exceptional performance and reliability, it is no surprise that a strategic partner has chosen to invest in this groundbreaking technology.

This financial boost will undoubtedly fuel the growth and expansion of Unit Curetis GmbH, allowing them to continue their mission of revolutionizing the medical industry. With the newfound resources, the company can further enhance their research and development efforts, ensuring the continuous improvement and innovation of their product range.

The success of this transaction is a testament to the dedication and hard work put in by the team at Unit Curetis GmbH. Their commitment to delivering top-notch solutions and forging meaningful partnerships has proven to be a winning formula.

As the date of October 11, 2023, marks this significant achievement for Unit Curetis GmbH, it also serves as a reminder of the company’s unwavering commitment to excellence. With this recent accomplishment, the future looks exceptionally promising for Curetis, as they continue to make strides in the medical field and positively impact countless lives.